HC Wainwright Issues Pessimistic Estimate for AQST Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for shares of Aquestive Therapeutics in a research report issued on Tuesday, February 3rd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.16) for the quarter, down from their prior estimate of ($0.15). The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Aquestive Therapeutics’ Q4 2026 earnings at ($0.17) EPS and FY2026 earnings at ($0.61) EPS.

Several other equities analysts have also recently issued reports on AQST. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen downgraded Aquestive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Piper Sandler raised their target price on Aquestive Therapeutics from $5.00 to $8.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Zacks Research raised Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 17th. Finally, Lake Street Capital set a $6.00 price objective on Aquestive Therapeutics in a report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $8.50.

Aquestive Therapeutics Trading Up 7.0%

Shares of NASDAQ AQST opened at $4.11 on Thursday. The firm has a fifty day simple moving average of $5.05 and a two-hundred day simple moving average of $5.20. Aquestive Therapeutics has a 12 month low of $2.12 and a 12 month high of $7.55. The firm has a market capitalization of $501.42 million, a PE ratio of -5.79 and a beta of 1.65.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The company had revenue of $12.81 million during the quarter, compared to the consensus estimate of $12.94 million.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in shares of Aquestive Therapeutics by 30.8% in the third quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company’s stock worth $31,651,000 after acquiring an additional 1,333,627 shares during the last quarter. Geode Capital Management LLC boosted its stake in Aquestive Therapeutics by 16.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,977,001 shares of the company’s stock worth $6,545,000 after purchasing an additional 276,295 shares in the last quarter. Pale Fire Capital SE boosted its stake in Aquestive Therapeutics by 25.5% in the 2nd quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company’s stock worth $5,549,000 after purchasing an additional 340,767 shares in the last quarter. Blue Owl Capital Holdings LP grew its position in Aquestive Therapeutics by 35.9% during the 3rd quarter. Blue Owl Capital Holdings LP now owns 1,250,000 shares of the company’s stock valued at $6,988,000 after purchasing an additional 330,000 shares during the last quarter. Finally, Commonwealth Equity Services LLC bought a new stake in Aquestive Therapeutics during the 3rd quarter valued at about $5,918,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.